3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
2
Phase 2
2
Phase 1
2
Phase NA
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Carcinoma, Non-Small-Cell Lung
50
Colorectal Neoplasms
29
Prostatic Neoplasms
28
Neoplasms
28
Breast Neoplasms
27
Neoplasm Metastasis
26
Multiple Myeloma
24
Pancreatic Neoplasms
22
Recurrence
18
Ovarian Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
17
Melanoma
17
Lymphoma, Non-Hodgkin
17
Triple Negative Breast Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
15
Leukemia, Myeloid, Acute
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Burkitt Lymphoma
14
Lung Neoplasms
13
Carcinoma, Renal Cell
13
Stomach Neoplasms
12
Lymphoma, Follicular
12
Lymphoma
12
Endometrial Neoplasms
12
Advanced Solid Tumors
12
Small Cell Lung Carcinoma
11
Glioblastoma
11
Colonic Neoplasms
11
Leukemia, Lymphocytic, Chronic, B-Cell
10
Uterine Cervical Neoplasms
9
Interventions
Docetaxel
2
olaparib
1
fludrocortisone acetate
1
enzalutamide
1
cabazitaxel
1
abiraterone
1
Prednisone
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms, Castration-Resistant
×
30 days
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled
NCT06863272
2026-05-15
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
360 enrolled
NCT04868604
2026-05-06
SECuRE
Clarity Pharmaceuticals Ltd
Phase 1/2
Recruiting
54 enrolled